Financial Data and Key Metrics Changes - The company reported total revenue of $97.7 million for Q2 2025, representing a 33% year-over-year growth compared to $73.2 million in Q2 2024 [25] - The net loss for Q2 2025 was approximately $19.1 million, or $0.08 per share, compared to a net loss of $16.5 million, or $0.07 per share in the same period last year [31] - The company ended Q2 2025 with $238.5 million in cash, cash equivalents, and short-term investments, including $48.7 million of incremental debt [32] Business Line Data and Key Metrics Changes - Ibsrela generated $65 million in net sales revenue for Q2 2025, reflecting an 84% year-over-year growth and a 46% quarter-over-quarter growth [6][11] - Exposa recorded net sales revenue of $25 million in Q2 2025, a 7% increase compared to Q1 2025, and a 27% increase when excluding a one-time reserve release from Q1 [7][28] Market Data and Key Metrics Changes - The demand for Ibsrela in Israel showed broad-based growth with record highs across all key indicators, leading to an increase in full-year guidance for net sales revenue to $250 million to $260 million [6] - Exposa's performance was driven by improved access for patients and growth in non-Medicare payer segments, indicating a positive response to promotional messaging from the sales team [18][19] Company Strategy and Development Direction - The company is focused on executing its commercial strategy effectively, with plans to continue expanding the prescribing base for both Ibsrela and Exposa [15][21] - The leadership team has been strengthened with new appointments to support the next phase of growth, including the promotion of Mike Kelleher to Chief Business Officer [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving peak sales of over $1 billion for Ibsrela and $750 million for Exposa, citing strong patient demand and improved prescription pull-through [16][21] - The company is optimistic about continued growth throughout 2025, with a focus on maintaining high execution levels [21] Other Important Information - The company has drawn an additional $50 million of debt to enhance financial flexibility, bringing total outstanding debt to $200 million [32] - The company has completed its $75 million royalty obligation to AstraZeneca, which is now behind them [30] Q&A Session Summary Question: Update on potential EU partner and cash flow positive status - Management indicated that achieving cash flow breakeven is a near-term goal and that they are evaluating opportunities in Europe [38] Question: Clarification on new guidance for Ibsrela - Management stated that the $10 million increase in guidance reflects a meaningful step forward and is based on thoughtful analysis [44] Question: Sales growth attribution to expanded sales team - Management confirmed that the expanded sales team has significantly contributed to the increase in prescriptions and expects this trend to continue [50][52] Question: Contribution from transitional scripts for Exposa - Management noted that there was an inconsequential amount of transitional scripts in Q2 and that the mix is roughly 50/50 between Medicaid and commercial [60][118] Question: Confidence in new peak estimate for Exposa - Management expressed confidence in the new peak estimate for Exposa, citing a total available market of 220,000 patients and strong performance indicators [86] Question: Update on CMS legal proceedings - Management confirmed that arguments for the ongoing CMS case will be heard on September 25, with no statutory requirement for a response timeframe [79]

Financial Performance - For 2024, the company generated $150 million in service revenue, a 10% increase over 2023, driven by growth in both business segments [8][10] - Total adjusted EBITDA for 2024 was $17.4 million, representing an $18.3 million improvement over 2023, largely from service revenue growth and higher adjusted EBITDA margins [8][10] - The business segments generated $44.6 million of adjusted EBITDA at 29.7% margins, reflecting a $10.4 million improvement and a 462 basis points increase in margins compared to 2023 [9][10] - The corporate segment's adjusted EBITDA loss declined by $7.9 million or 22% to $27.2 million, primarily due to efficiency initiatives [10][22] Business Segment Performance - The Servicer and Real Estate segment had service revenue of $120 million, an 11% increase from 2023, with adjusted EBITDA of $42.1 million, up $5 million or 14% [17][18] - The Origination segment reported service revenue of $30.4 million, a 6% increase from 2023, with adjusted EBITDA improving by $5.4 million to $2.5 million [20][21] - The corporate segment's adjusted EBITDA loss improved due to cost savings and efficiency initiatives [22] Market Conditions - The default market has faced challenges, with 2024 foreclosure starts 35% lower than 2019 levels and 6% lower than 2023 [23] - The origination market also struggled, with 2024 mortgage origination volume 35% lower than 2019 levels, although it was higher than 2023 due to refinance activity [24] Company Strategy and Outlook - The company aims to diversify its revenue base and ramp up business won while maintaining cost discipline and reducing corporate interest expense [28] - For 2025, the company forecasts service revenue between $165 million and $185 million, representing 16% growth, and adjusted EBITDA of $18 million to $23 million, indicating 18% growth [26][27] - The company is focusing on accelerating growth in certain businesses that have favorable market conditions and expects to benefit from a return to normalcy in the default market [28] Management Commentary - Management expressed optimism about the company's strong start to 2025, with January revenue and EBITDA results exceeding expectations [42] - The company is monitoring market conditions closely, particularly regarding delinquency rates and potential increases in foreclosure starts [50][51] Other Important Information - In February 2025, the company executed a transaction with lenders that significantly strengthened its balance sheet, reducing debt from $233 million to $172.5 million [12][14] - The interest rate on the new term loan is SOFR plus 650 basis points, resulting in a significant reduction in annual cash interest costs [13][62] Q&A Session Summary Question: Can you comment on the nature of some of the wins you've had across originations and servicing? - Management highlighted successful initiatives in the construction renovation and Lenders One origination businesses, with both achieving over $1 million in monthly revenue [34][36] Question: How are things trending thus far in 2025? - Management reported a strong start to the year, with January revenue and EBITDA results aligning with or exceeding plans [42] Question: When do you expect foreclosure starts to impact results? - Management noted that while they are being conservative in forecasting, there are indications from clients that foreclosure starts may increase [48][50] Question: Are there other agencies implementing policies that might impact the business? - Management mentioned the FHA's new programs and the potential for increased delinquencies as borrowers exhaust modification options [54][56] Question: Will there be a sizable gain in Q1 that could reduce negative equity? - Management indicated that while interest expenses will decrease significantly, they are still finalizing accounting related to the recent transaction [60][62]